S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$29.42
+0.46 (+1.59%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$28.36
$29.51
50-Day Range
$26.24
$34.92
52-Week Range
$13.15
$39.85
Volume
265,500 shs
Average Volume
497,654 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.22

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
60.5% Upside
$47.22 Price Target
Short Interest
Bearish
21.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Kymera Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$42,470 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.66) to ($3.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

866th out of 1,012 stocks

Biological Products, Except Diagnostic Industry

140th out of 169 stocks


KYMR stock logo

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Stock News Headlines

Kymera Appoints Jeremy Chadwick As COO
Kymera Therapeutics appoints COO
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Kymera: More Data Needed
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Kymera Therapeutics (KYMR) Gets a Buy from H.C. Wainwright
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings
5/04/2023
Today
5/28/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KYMR
Fax
N/A
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.22
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+60.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-154,810,000.00
Net Margins
-340.80%
Pretax Margin
-340.80%

Debt

Sales & Book Value

Annual Sales
$46.83 million
Book Value
$8.35 per share

Miscellaneous

Free Float
45,900,000
Market Cap
$1.63 billion
Optionable
Not Optionable
Beta
1.71

Key Executives

  • Dr. Bruce L. Booth D.Phil. (Age 49)
    DPHIL, Ph.D., Co-Founder & Chairman
    Comp: $73k
  • Dr. Nello Mainolfi M.D. (Age 44)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $940.11k
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jared A. Gollob M.D. (Age 58)
    Chief Medical Officer
    Comp: $676.75k
  • Ms. Elaine Caughey
    Chief Bus. Officer
  • Kevin Dushney
    Sr. VP of IT & Operations
  • Mr. Michael J. Todisco (Age 58)
    VP of Accounting & Fin.
  • Mr. Vijay Sabesan (Age 51)
    Sr. VP of Technical Operations
  • Ms. Melissa Brody
    VP of Bus. Devel.
  • Ms. Karen Weisbach
    VP of People & Culture













KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KYMR shares.
View KYMR analyst ratings
or view top-rated stocks.

What is Kymera Therapeutics' stock price forecast for 2023?

8 brokerages have issued 12-month target prices for Kymera Therapeutics' shares. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's share price to reach $47.22 in the next year. This suggests a possible upside of 60.5% from the stock's current price.
View analysts price targets for KYMR
or view top-rated stocks among Wall Street analysts.

How have KYMR shares performed in 2023?

Kymera Therapeutics' stock was trading at $24.96 at the beginning of the year. Since then, KYMR shares have increased by 17.9% and is now trading at $29.42.
View the best growth stocks for 2023 here
.

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our KYMR earnings forecast
.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.01. The firm had revenue of $9.47 million for the quarter, compared to analysts' expectations of $14.15 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.15% and a negative net margin of 340.80%. The business's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.71) earnings per share.

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (10.59%), BVF Inc. IL (8.57%), Price T Rowe Associates Inc. MD (8.44%), Wellington Management Group LLP (7.76%), Avoro Capital Advisors LLC (6.97%) and BlackRock Inc. (6.02%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends
.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $29.42.

How much money does Kymera Therapeutics make?

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $1.63 billion and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.

How many employees does Kymera Therapeutics have?

The company employs 141 workers across the globe.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -